See more : XIAMEN YAN PALACE BIRD’S NEST INDUS (1497.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Cerus Corporation (CERS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cerus Corporation, a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Hello Pal International Inc. (HP.CN) Income Statement Analysis – Financial Results
- Aida Pharmaceuticals, Inc. (AIDA) Income Statement Analysis – Financial Results
- Energy Resources of Australia Ltd (ERA.AX) Income Statement Analysis – Financial Results
- Zhongguancun Science-Tech Leasing Co., Ltd. (1601.HK) Income Statement Analysis – Financial Results
- Shi Corporation (SHCC) Income Statement Analysis – Financial Results
Cerus Corporation (CERS)
About Cerus Corporation
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was incorporated in 1991 and is headquartered in Concord, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 156.37M | 162.05M | 130.86M | 91.92M | 74.65M | 60.91M | 43.57M | 37.18M | 34.22M | 36.50M | 39.66M | 36.70M | 33.04M | 23.11M | 17.98M | 16.51M | 11.04M | 35.58M | 24.37M | 13.91M | 9.67M | 8.49M | 4.54M | 1.85M | 2.40M | 2.90M | 6.90M |
| Cost of Revenue | 69.97M | 74.95M | 63.48M | 41.16M | 33.42M | 31.63M | 22.53M | 20.30M | 23.46M | 21.18M | 22.60M | 20.62M | 18.54M | 12.05M | 12.58M | 9.67M | 5.23M | 1.54M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -634.00K | -600.00K | -700.00K | -700.00K |
| Gross Profit | 86.40M | 87.09M | 67.38M | 50.76M | 41.23M | 29.27M | 21.04M | 16.89M | 10.76M | 15.33M | 17.06M | 16.08M | 14.51M | 11.06M | 5.40M | 6.84M | 5.82M | 34.04M | 24.37M | 13.91M | 9.67M | 8.49M | 4.54M | 2.49M | 3.00M | 3.60M | 7.60M |
| Gross Profit Ratio | 55.25% | 53.75% | 51.49% | 55.23% | 55.23% | 48.06% | 48.29% | 45.42% | 31.44% | 41.99% | 43.01% | 43.82% | 43.91% | 47.87% | 30.04% | 41.43% | 52.66% | 95.67% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 134.25% | 125.00% | 124.14% | 110.14% |
| Research & Development | 67.64M | 64.11M | 63.69M | 64.41M | 60.38M | 42.56M | 33.71M | 31.32M | 25.64M | 21.69M | 15.19M | 7.60M | 7.18M | 5.20M | 6.37M | 10.21M | 14.96M | 29.51M | 24.13M | 27.65M | 52.48M | 56.42M | 48.25M | 34.82M | 22.50M | 29.80M | 19.60M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 56.84M | 52.41M | 48.75M | 45.99M | 37.73M | 29.97M | 25.67M | 23.05M | 21.58M | 21.87M | 27.16M | 24.58M | 14.01M | 9.58M | 10.23M | 11.02M | 11.35M | 10.17M | 7.16M | 4.80M | 3.80M | 3.20M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 56.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 75.52M | 83.34M | 81.29M | 67.02M | 66.21M | 56.84M | 52.41M | 48.75M | 45.99M | 37.79M | 29.97M | 25.67M | 23.05M | 21.58M | 21.87M | 27.16M | 24.58M | 14.01M | 9.58M | 10.23M | 11.02M | 11.35M | 10.17M | 7.16M | 4.80M | 3.80M | 3.20M |
| Other Expenses | 0.00 | -26.27M | -28.66M | -22.33M | -19.13M | 1.75M | 3.86M | -1.28M | 71.00K | 130.00K | 266.00K | 31.00K | 202.00K | 67.00K | 155.00K | 0.00 | 9.45M | 0.00 | 0.00 | 2.86M | 0.00 | 0.00 | 0.00 | 634.00K | 600.00K | 700.00K | 700.00K |
| Operating Expenses | 115.34M | 121.18M | 116.32M | 109.10M | 107.46M | 84.26M | 78.57M | 78.19M | 71.83M | 59.68M | 45.35M | 33.38M | 30.43M | 26.84M | 28.39M | 37.37M | 48.98M | 43.52M | 33.71M | 37.88M | 63.50M | 67.77M | 58.41M | 42.62M | 27.90M | 34.30M | 23.50M |
| Cost & Expenses | 185.30M | 196.13M | 179.80M | 150.25M | 140.88M | 115.90M | 101.10M | 98.48M | 95.30M | 80.85M | 67.96M | 54.00M | 48.97M | 38.89M | 40.97M | 47.04M | 54.21M | 45.06M | 33.71M | 37.88M | 63.50M | 67.77M | 58.41M | 41.98M | 27.30M | 33.60M | 22.80M |
| Interest Income | 0.00 | 5.83M | 4.92M | 3.75M | 6.07M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 8.39M | 5.83M | 4.92M | 3.75M | 6.07M | 4.01M | 3.02M | 2.45M | 1.71M | 599.00K | 520.00K | 551.00K | 964.00K | 689.00K | 302.00K | 10.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 2.60M | 4.56M | 4.57M | 4.46M | 2.40M | 1.45M | 1.81M | 1.82M | 202.00K | 202.00K | 202.00K | 202.00K | 922.00K | 845.00K | 915.00K | 651.00K | 774.00K | 716.00K | 652.00K | 2.15M | 3.29M | 2.50M | 1.19M | 634.00K | 600.00K | 700.00K | 700.00K |
| EBITDA | -26.54M | -34.08M | -45.99M | -51.37M | -64.61M | -51.88M | -51.87M | -58.47M | -56.14M | -36.55M | -42.04M | -14.38M | -15.10M | -15.38M | -22.92M | -28.53M | -43.17M | -4.06M | -8.69M | -23.01M | -50.54M | -56.78M | -52.69M | -39.51M | -24.29M | -30.00M | -15.20M |
| EBITDA Ratio | -16.97% | -21.03% | -37.40% | -63.46% | -88.72% | -90.28% | -131.58% | -163.91% | -177.66% | -120.94% | -70.85% | -46.59% | -45.40% | -64.61% | -123.18% | -181.01% | -298.28% | -24.63% | -126.29% | -136.45% | -522.96% | -668.79% | -1,161.74% | -2,133.93% | -1,012.50% | -1,075.86% | -237.68% |
| Operating Income | -30.05M | -34.08M | -48.94M | -58.33M | -66.23M | -54.99M | -57.53M | -61.45M | -61.08M | -44.35M | -28.30M | -17.30M | -15.92M | -15.96M | -23.83M | -30.53M | -43.17M | -9.48M | -9.34M | -26.83M | -53.84M | -59.28M | -53.88M | -40.13M | -24.90M | -30.70M | -15.90M |
| Operating Income Ratio | -19.22% | -21.03% | -37.40% | -63.46% | -88.72% | -90.28% | -132.05% | -165.26% | -178.46% | -121.49% | -71.36% | -47.15% | -48.19% | -69.06% | -132.54% | -184.95% | -390.85% | -26.64% | -38.33% | -192.84% | -557.01% | -698.20% | -1,188.05% | -2,168.18% | -1,037.50% | -1,058.62% | -230.43% |
| Total Other Income/Expenses | -7.27M | -8.26M | -5.12M | -1.24M | -4.76M | -2.35M | 832.00K | -1.28M | 1.54M | 5.94M | -14.82M | 1.63M | -1.06M | -953.00K | -302.00K | 1.35M | 4.07M | 4.70M | 22.41M | -4.33M | -4.43M | 2.09M | 4.61M | 4.10M | 0.00 | 1.20M | 1.20M |
| Income Before Tax | -37.32M | -42.34M | -54.06M | -59.57M | -70.98M | -57.34M | -56.70M | -62.73M | -59.54M | -38.37M | -43.12M | -15.68M | -16.98M | -16.91M | -24.67M | 0.00 | -52.62M | -4.78M | 12.75M | -31.15M | -4.43M | -57.19M | -49.27M | -36.03B | 0.00 | -29.50M | -14.70M |
| Income Before Tax Ratio | -23.87% | -26.13% | -41.31% | -64.81% | -95.09% | -94.13% | -130.14% | -168.71% | -173.97% | -105.12% | -108.73% | -42.72% | -51.39% | -73.18% | -137.21% | 0.00% | -476.42% | -13.43% | 52.31% | -223.95% | -45.86% | -673.64% | -1,086.37% | -1,946,682.93% | 0.00% | -1,017.24% | -213.04% |
| Income Tax Expense | 325.00K | 488.00K | 319.00K | 284.00K | 263.00K | 229.00K | 3.89M | 175.00K | -3.67M | 195.00K | 218.00K | 242.00K | 964.00K | 689.00K | 228.00K | -1.35M | 2.14M | 0.00 | -22.41M | 7.19M | 53.84M | 0.00 | 100.00K | 4.10B | -2.30M | -1.10M | -1.20M |
| Net Income | -37.49M | -42.83M | -54.38M | -59.86M | -71.24M | -57.56M | -60.59M | -62.91M | -55.87M | -38.57M | -43.34M | -15.92M | -16.98M | -16.91M | -24.14M | -29.18M | -45.30M | -4.78M | 13.06M | -31.15M | -58.27M | -57.19M | -49.37M | -36.03M | -22.60M | -29.60M | -14.70M |
| Net Income Ratio | -23.98% | -26.43% | -41.55% | -65.12% | -95.44% | -94.51% | -139.06% | -169.18% | -163.25% | -105.65% | -109.28% | -43.38% | -51.39% | -73.18% | -134.22% | -176.78% | -410.21% | -13.43% | 53.60% | -223.95% | -602.87% | -673.64% | -1,088.58% | -1,946.68% | -941.67% | -1,020.69% | -213.04% |
| EPS | -0.21 | -0.24 | -0.32 | -0.37 | -0.51 | -0.44 | -0.56 | -0.62 | -0.58 | -0.52 | -0.64 | -0.29 | -0.35 | -0.42 | -0.69 | -0.90 | -1.42 | -0.18 | 0.58 | -1.41 | -3.01 | -3.61 | -3.27 | -2.75 | -2.04 | -3.17 | -1.76 |
| EPS Diluted | -0.21 | -0.24 | -0.32 | -0.37 | -0.51 | -0.44 | -0.56 | -0.62 | -0.58 | -0.50 | -0.64 | -0.29 | -0.35 | -0.42 | -0.69 | -0.90 | -1.42 | -0.17 | 0.55 | -1.41 | -3.01 | -3.61 | -3.27 | -2.75 | -2.04 | -3.17 | -1.76 |
| Weighted Avg Shares Out | 180.27M | 176.55M | 171.28M | 163.95M | 139.83M | 130.83M | 108.19M | 101.46M | 96.07M | 74.77M | 67.57M | 54.52M | 48.05M | 40.30M | 34.75M | 32.43M | 31.87M | 26.87M | 22.35M | 22.14M | 19.37M | 15.83M | 15.11M | 13.09M | 11.10M | 9.33M | 8.35M |
| Weighted Avg Shares Out (Dil) | 180.27M | 176.55M | 171.28M | 163.95M | 139.83M | 131.66M | 108.22M | 101.83M | 96.91M | 76.53M | 67.57M | 55.06M | 48.05M | 40.30M | 34.75M | 32.43M | 31.87M | 28.61M | 23.95M | 22.14M | 19.37M | 15.83M | 15.11M | 13.09M | 11.10M | 9.33M | 8.35M |
Cerus Corporation Celebrates World Blood Donor Day 2023
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) is proud to announce its celebration of World Blood Donor Day 2023. In 2005, the World Health Assembly designated June 14 as World Blood Donor Day to recognize and thank blood donors across the...
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
Cathie Wood bought shares of Coinbase, Rocket Lab, and Cerus on Tuesday. Coinbase has surrendered 20% of its value in the last two days as regulatory risks rise.
Cerus Corporation Announces Follow-on Award of U.S. Department of Defense Funding for Development of Pathogen Reduced, Lyophilized Cryoprecipitate
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced that it has been awarded an additional $8.7 million contract amendment to the original $9.1 million contract by the U.S. Department of Defense (DoD) Industrial Base Analysis and Sustainment (IBAS) program for...
Cerus Corporation: Cash Burn Remains Concerning
Today, we put medical device concern Cerus Corporation in the spotlight. Cerus has some current challenges, which management believes are temporary. Sales growth is projected to accelerate significantly in FY2024.
Cerus (CERS) Reports Q1 Loss, Lags Revenue Estimates
Cerus (CERS) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.07 per share a year ago.
Cerus Corporation Announces First Quarter 2023 Financial Results
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced financial results for the first quarter ended March 31, 2023. Recent highlights include: First quarter 2023 total revenue of $38.5 million was comprised of (in thousands, except %): ...
7 Best Cathie Wood Stocks for Your May 2023 Buy List
Cathie Wood invests in speculative stocks that don't always pan out, as 2022 showed. The chief of Ark Investment Management watched her firm outperform in 2021, though last year saw a sharp deceleration in interest in various hough-growth names.
Global Carbon Credit Market 2023 - 2028: Growing Coverage of Carbon Pricing Initiatives Fuels the Sector - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Global Carbon Credit Market: Analysis by Traded Value, Traded Volume, Segment, Project Category, Region, Size and Trends with Impact of COVID-19 and Forecast up to 2028" report has been added to ResearchAndMarkets.com's offering. The global carbon credit market...
Cerus Corporation to Release First Quarter 2023 Financial Results on May 4, 2023
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that its first quarter 2023 financial results will be released on Thursday, May 4, 2023, after the close of the stock market. The Company will host a conference call and webcast at...
Cerus Corporation to Release First Quarter 2023 Financial Results on May 4, 2023
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that its first quarter 2023 financial results will be released on Thursday, May 4, 2023, after the close of the stock market. The Company will host a conference call and webcast at...
Source: https://incomestatements.info
Category: Stock Reports